Comparative Pharmacology
Head-to-head clinical analysis: OZEMPIC versus SAXENDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZEMPIC versus SAXENDA.
OZEMPIC vs SAXENDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of endogenous GLP-1, which increases insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. The primary mechanism is activation of GLP-1 receptors on pancreatic beta cells, leading to glucose-dependent insulin release.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety via central GLP-1 receptor activation.
1 mg subcutaneously once weekly, starting at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks before escalating to 1 mg.
Subcutaneous injection once daily, starting at 0.6 mg and titrating weekly by 0.6 mg increments to a maintenance dose of 3.0 mg.
None Documented
None Documented
Terminal elimination half-life approximately 1 week (5–7 days) in subcutaneous dosing, allowing once-weekly administration. Steady state reached after 4–5 weeks.
11–13 hours (subcutaneous). Steady-state is reached after 3–5 once-daily doses.
Primarily renal (80%) and biliary/fecal (20%). Unchanged parent drug accounts for ~5-10%; majority is degraded into small peptides/amino acids.
Renal excretion of intact liraglutide is minimal; approximately 6% is excreted as intact liraglutide in urine. The remainder is metabolized and eliminated via the kidneys and feces, with no single metabolite accounting for >10% of the dose.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist, Anti-obesity